Logo image of GRDX

GRIDAI TECHNOLOGIES CORP (GRDX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:GRDX - US33749P5070 - Common Stock

2.94 USD
-0.19 (-6.07%)
Last: 12/12/2025, 4:04:16 PM
Fundamental Rating

1

Overall GRDX gets a fundamental rating of 1 out of 10. We evaluated GRDX against 531 industry peers in the Biotechnology industry. GRDX has a bad profitability rating. Also its financial health evaluation is rather negative. GRDX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

GRDX had negative earnings in the past year.
In the past year GRDX has reported a negative cash flow from operations.
GRDX had negative earnings in each of the past 5 years.
In the past 5 years GRDX always reported negative operating cash flow.
GRDX Yearly Net Income VS EBIT VS OCF VS FCFGRDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

GRDX's Return On Assets of -20.48% is fine compared to the rest of the industry. GRDX outperforms 75.52% of its industry peers.
The Return On Equity of GRDX (-31.45%) is better than 75.33% of its industry peers.
Industry RankSector Rank
ROA -20.48%
ROE -31.45%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GRDX Yearly ROA, ROE, ROICGRDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

1.3 Margins

GRDX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GRDX Yearly Profit, Operating, Gross MarginsGRDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2023 2024

More info and screens

3

2. Health

2.1 Basic Checks

Compared to 1 year ago, GRDX has more shares outstanding
There is no outstanding debt for GRDX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
GRDX Yearly Shares OutstandingGRDX Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 500K 1M 1.5M
GRDX Yearly Total Debt VS Total AssetsGRDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

GRDX has an Altman-Z score of -2.58. This is a bad value and indicates that GRDX is not financially healthy and even has some risk of bankruptcy.
GRDX's Altman-Z score of -2.58 is in line compared to the rest of the industry. GRDX outperforms 46.14% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that GRDX is not too dependend on debt financing.
GRDX's Debt to Equity ratio of 0.01 is in line compared to the rest of the industry. GRDX outperforms 43.50% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -2.58
ROIC/WACCN/A
WACCN/A
GRDX Yearly LT Debt VS Equity VS FCFGRDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 2.81 indicates that GRDX has no problem at all paying its short term obligations.
GRDX has a Current ratio of 2.81. This is in the lower half of the industry: GRDX underperforms 67.61% of its industry peers.
A Quick Ratio of 2.81 indicates that GRDX has no problem at all paying its short term obligations.
GRDX has a Quick ratio of 2.81. This is in the lower half of the industry: GRDX underperforms 65.72% of its industry peers.
Industry RankSector Rank
Current Ratio 2.81
Quick Ratio 2.81
GRDX Yearly Current Assets VS Current LiabilitesGRDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 76.71% over the past year.
EPS 1Y (TTM)76.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.12%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -13.45% on average over the next years. This is quite bad
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-34.51%
EPS Next 2Y-24.09%
EPS Next 3Y-13.45%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GRDX Yearly EPS VS EstimatesGRDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -100K -200K -300K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

GRDX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year GRDX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GRDX Price Earnings VS Forward Price EarningsGRDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GRDX Per share dataGRDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10 15

4.3 Compensation for Growth

GRDX's earnings are expected to decrease with -13.45% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-24.09%
EPS Next 3Y-13.45%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GRDX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GRIDAI TECHNOLOGIES CORP

NASDAQ:GRDX (12/12/2025, 4:04:16 PM)

2.94

-0.19 (-6.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-11 2025-11-11
Earnings (Next)03-30 2026-03-30/amc
Inst Owners4.54%
Inst Owner ChangeN/A
Ins Owners2.89%
Ins Owner ChangeN/A
Market Cap9.88M
Revenue(TTM)N/A
Net Income(TTM)-17.42M
Analysts43.33
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.18
P/tB 0.18
EV/EBITDA N/A
EPS(TTM)-11.09
EYN/A
EPS(NY)-1.77
Fwd EYN/A
FCF(TTM)-0.86
FCFYN/A
OCF(TTM)-0.86
OCFYN/A
SpS0
BVpS16.48
TBVpS15.98
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -20.48%
ROE -31.45%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.81
Quick Ratio 2.81
Altman-Z -2.58
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)76.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.12%
EPS Next Y-34.51%
EPS Next 2Y-24.09%
EPS Next 3Y-13.45%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y77.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y25.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y25.53%
OCF growth 3YN/A
OCF growth 5YN/A

GRIDAI TECHNOLOGIES CORP / GRDX FAQ

What is the fundamental rating for GRDX stock?

ChartMill assigns a fundamental rating of 1 / 10 to GRDX.


What is the valuation status for GRDX stock?

ChartMill assigns a valuation rating of 0 / 10 to GRIDAI TECHNOLOGIES CORP (GRDX). This can be considered as Overvalued.


How profitable is GRIDAI TECHNOLOGIES CORP (GRDX) stock?

GRIDAI TECHNOLOGIES CORP (GRDX) has a profitability rating of 1 / 10.


Can you provide the financial health for GRDX stock?

The financial health rating of GRIDAI TECHNOLOGIES CORP (GRDX) is 3 / 10.